investors.rxipharma.com
Officers & Directors - RXi PharmaceuticalsRXi Pharmaceuticals
http://investors.rxipharma.com/od.aspx?iid=4418218
Partnering and Licensing Opportunities. Geert Cauwenbergh, Dr. Med. Sc. President and Chief Executive Officer. Pamela Pavco, Ph.D. Lyn Libertine, M.D. Vice President Medical Affairs and Safety Assessment. Karen Bulock, Ph.D. Geert Cauwenbergh, Dr. Med. Sc. Curtis Lockshin, Ph.D. Craig C. Mello, Ph.D. Peter Campochiaro, M.D. Jeannette Graf, M.D. Leroy Young, M.D. Marlborough, MA 01752. S&P Global Market Intelligence. TERMS AND CONDITIONS OF USE. These Terms of Use are the entire agreement between the part...
investors.rxipharma.com
Email Notification - RXi PharmaceuticalsRXi Pharmaceuticals
http://investors.rxipharma.com/email.aspx?iid=4418218
Partnering and Licensing Opportunities. Please select from the following options to receive an email with new items of interest. Notify me of any newly scheduled corporate events. Remind me two business days before any event. Notify me of all new company documents. Notify me of any new company documents, except insider trading documents. News / Press Releases. Notify me of company news/press releases. Notify me with an end-of-day stock quote. Notify me of presentations. Edit Existing Notification Request:.
investors.rxipharma.com
Stock Information - RXi PharmaceuticalsRXi Pharmaceuticals
http://investors.rxipharma.com/stockinfo.aspx?iid=4418218
Partnering and Licensing Opportunities. Select link to view descriptions of our traded funding issues. Historic Price Look Up. Enter a date below to request the closing price for that specific day:. Marlborough, MA 01752. S&P Global Market Intelligence. TERMS AND CONDITIONS OF USE. The Site does not represent an offer or solicitation with respect to the purchase or sale of any security. These Terms of Use are the entire agreement between the parties with respect to its subject matter, and it can be amend...
sdgpennystocks.blogspot.com
Shareholder Development Group: RXi Pharmaceuticals Provides Update and Reports Financial Results for Q2 2011
http://sdgpennystocks.blogspot.com/2011/08/rxi-pharmaceuticals-provides-update-and.html
Tuesday, August 16, 2011. RXi Pharmaceuticals Provides Update and Reports Financial Results for Q2 2011. NeuVax™ (E75) makes significant progress towards initiating the Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment) study in 1H, 2012. WORCESTER, Mass., Aug. 15, 2011 (GLOBE NEWSWIRE) — RXi Pharmaceuticals Corporation (Nasdaq: RXII. Dr Beth Mittendorf announced as the Phase 3 Principle Investigator.
advirna.com
About — Advirna
http://advirna.com/about-us
Developing improved tools to manipulate and study the activity of genes in living cells. Founded by Anastasia Khvorova, PhD and Alexey Wolfson, PhD in 2007 to develop new nucleic based technologies for therapeutic and research use. Advirna has developed a proprietary self-deliverable RNAi technology and reduced it to practice in collaboration with RXi Pharmaceuticals. Advirna's platform provides researchers with better tools to study and manipulate activity of genes in living cells. Tod Woolf, PhD.
healthtech.com
Targeting Ocular Disorders - Overview
http://www.healthtech.com/targeting-ocular-disorders
With its complex structure and the breadth of ocular disorders, the eye presents unique challenges to drug discovery. Cambridge Healthtech Institute’s fourth annual Targeting Ocular Disorders. September 20-21 Conference: Targeting Ocular Disorders. September 21-22 Conference: Advances in Gene Editing and Gene Silencing - Part 2. Day 1 Day 2. Tuesday, September 20. 7:00 am Registration Open and Morning Coffee. STEM CELLS FOR OCULAR DISORDERS. 8:05 Chairperson’s Opening Remarks. Human umbilical tissue cell...
sdgpennystocks.blogspot.com
Shareholder Development Group: August 2011
http://sdgpennystocks.blogspot.com/2011_08_01_archive.html
Tuesday, August 16, 2011. Clinical Investigators to Present Data on Nymox BPH Drug at American Urological Association Meeting October 19. HASBROUCK HEIGHTS, N.J., Aug. 16, 2011 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (Nasdaq: NYMX. Or contact Nymox at info@nymox.com. Supportcomm Selects Motricity to Expand Its Mobile Capabilities for More Than 200 Million Subscribers in Latin America. 41; to expand its mobile services platform in Latin America. Implementing Motricity’s technology to...8220;Br...
SOCIAL ENGAGEMENT